Methotrexat Medac

Methotrexate, the active ingredient in Methotrexat Medac, is an antimetabolite (folate antagonist) presented as a sterile injectable for intra‑arterial, intramuscular, and intravenous use. It is employed in the management of rheumatoid arthritis, severe psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma, breast cancer, and ectopic pregnancy in suitable patients, under specialist supervision and as part of a comprehensive therapeutic regimen.

GNH USA supplies Methotrexat Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Methotrexate is used in several disease categories that involve abnormal cell proliferation or immune dysregulation. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: limits skin cell overgrowth and improves lesions. - Acute lymphoblastic leukemia: interferes with malignant cell replication. - Non‑Hodgkin lymphoma: suppresses tumor growth. - Breast cancer: enhances the effect of other chemotherapeutic agents. - Ectopic pregnancy: terminates trophoblastic tissue non‑surgically.

Methotrexate may cause a range of adverse reactions.

Common Side Effects: - Nausea and vomiting. - Fatigue and malaise. - Oral mucositis or mouth sores. - Transient elevation of liver enzymes. - Mild cytopenias (low white blood cells or platelets). - Skin rash or mild photosensitivity.

Serious or Rare Side Effects: - Severe hepatotoxicity or liver fibrosis. - Pulmonary toxicity, including interstitial pneumonitis. - Life‑threatening bone marrow suppression. - Acute renal failure. - Severe cutaneous adverse reactions (e.g., Stevens‑Johnson syndrome). - Opportunistic infections due to immunosuppression.

Methotrexate requires careful monitoring and specific safety measures. - Pregnancy: contraindicated (Category X) – avoid use in pregnant patients. - Renal function: assess baseline and monitor; adjust dose if impaired. - Hepatic function: regularly check liver enzymes and consider dose reduction for abnormalities. - Hematologic monitoring: perform frequent blood counts to detect marrow suppression. - Infection risk: postpone therapy in active infections and monitor for opportunistic infections. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Methotrexate interacts with several medicines that may alter its safety or efficacy.

Major Interactions (Avoid): - NSAIDs (e.g., ibuprofen): increase methotrexate toxicity. - Penicillins (e.g., ampicillin): reduce methotrexate clearance. - Live vaccines: heightened risk of severe infection. - Sulfonamides: additive bone‑marrow suppression. - Trimethoprim: may increase methotrexate toxicity.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect absorption. - Azathioprine: additive immunosuppressive effect. - Allopurinol: potential increase in toxicity.